FDA Approves First Generic HIV Prevention Shot at $40 a Year for 120 Countries

The U.S. Food and Drug Administration has granted tentative approval to the first generic HIV prevention shot, a twice-yearly injectable lenacapavir that will cost just $40 per person per year in 120 low- and middle-income countries. The decision, announced on Monday, November 2, 2026, arrives only 16 months after Gilead's branded version was approved for HIV prevention in June 2025, and it could transform prevention for millions of people who struggle with a daily pill.

The generic HIV prevention shot was developed by India-based Dr. Reddy's Laboratories under an agreement brokered by Unitaid, the Clinton Health Access Initiative (CHAI) and Wits RHI, after Gilead granted voluntary licences to six generic manufacturers in late 2024. Under a pricing agreement reached in September 2025, Dr. Reddy's lenacapavir will be available at $40 per person per year in the countries covered by Gilead's voluntary licence, compared with a U.S. list price of about $28,000 to $28,218 a year for the branded product, sold as Yeztugo.

The injection is given only twice a year and was more than 99.9% effective in large trials, offering a powerful alternative to daily oral pre-exposure prophylaxis, known as PrEP. Tentative approval is the FDA's standard designation while the originator medicine remains under patent. It enables U.S. government procurement, although the generic cannot itself be sold in the United States. First supplies are expected before the end of 2026, with broader availability in 2027.

Key Points

• The FDA granted tentative approval on November 2, 2026, to the first generic long-acting injectable lenacapavir for HIV prevention.
• The generic, made by Dr. Reddy's Laboratories, will cost $40 per person per year in 120 low- and middle-income countries, versus about $28,000 a year for the branded version in the U.S.
• The shot is given twice a year and was more than 99.9% effective in large clinical trials.
• More than 125,000 people in 10 early-adopter African countries have already started Gilead's branded lenacapavir.
• First generic supplies are expected before the end of 2026, with broader availability in 2027, but the generic cannot be sold in the United States while the patent stands.

What Happened

The FDA's tentative approval covers Dr. Reddy's generic version of lenacapavir, a long-acting injectable medicine used to prevent HIV infection in people at risk. The announcement was made on Monday, November 2, 2026, and was reported by CHAI, which helped broker the deal that made the generic possible. The speed is striking: Gilead's originator product was approved for HIV prevention only in June 2025, meaning a generic version has followed in just over a year.

Background and Context

HIV prevention has long depended heavily on daily oral PrEP, a pill that must be taken every day to work reliably. For many people, that daily routine is difficult to maintain. Doses are missed, prescriptions lapse, and stigma can make carrying or collecting daily pills a barrier in itself. Long-acting injectable prevention was designed to solve that problem: one injection, given by a health worker, protects for months at a time.

Lenacapavir is the most promising of these long-acting options so far. In large trials, it proved more than 99.9% effective at preventing HIV infection, a result that stunned researchers and advocates when the data first emerged. The branded version, Yeztugo, was approved in the United States in June 2025, but its list price of roughly $28,000 a year put it far out of reach for health systems in Africa and other regions where HIV rates are highest and budgets are tightest.

Generic HIV Prevention Shot: How the $40 Price Works

The $40-a-year price applies in the 120 low- and middle-income countries covered by Gilead's voluntary licence. That figure covers a full year of prevention: two injections, given six months apart. By comparison, the branded product's U.S. list price of about $28,000 a year is roughly 700 times higher, although list prices do not always reflect what insurers or programmes actually pay.

Reactions and Statements

Global health organisations involved in the deal have presented the approval as a landmark for HIV prevention, arguing that a $40-a-year injectable option could finally make the most effective prevention tool available at a scale to match the need. CHAI, which announced the approval, has long argued that long-acting prevention only fulfils its promise if it is affordable in the countries where HIV transmission remains highest.

Why It Matters

HIV still infects well over a million people a year worldwide, and prevention has stalled in many regions because the tools that work best have not been the tools most people can actually use. A twice-yearly injection that is more than 99.9% effective, at $40 a year, changes that calculation for health ministries deciding how to spend limited budgets.

It also matters for equity. The countries covered by the licence are precisely those where daily PrEP programmes have struggled with adherence and where clinic capacity is stretched. Two visits a year is a far lighter burden on both patients and health systems than daily pills or monthly injections. If rollout is handled well, the generic could help close the gap between what HIV science can do and what HIV programmes can deliver.

What Happens Next

First supplies of the generic are expected to reach countries before the end of 2026, with broader availability in 2027. The immediate next steps involve procurement decisions by governments and global health funders, regulatory approvals in individual countries, and the practical work of training health workers and stocking clinics.

Watch for announcements from the other five licensed generic manufacturers, whose own approvals could expand supply and competition. Longer term, researchers will track real-world uptake: how many people start the injection, how many return for the second dose six months later, and whether new HIV infections fall in communities where the generic is widely available.

Frequently Asked Questions

What is lenacapavir?

Lenacapavir is a long-acting injectable medicine that prevents HIV infection. It is given by a health worker twice a year, rather than as a daily pill.

How effective is the shot?

In large clinical trials, lenacapavir was more than 99.9% effective at preventing HIV infection.

Why does the generic cost $40 a year?

Dr. Reddy's generic is priced at $40 per person per year under a September 2025 agreement for the 120 countries covered by Gilead's voluntary licence, compared with about $28,000 a year for the branded U.S. product.

Can the generic be bought in the United States?

No. Tentative FDA approval enables U.S. government procurement for use abroad, but the generic cannot be sold in the United States while the originator remains under patent.

When will the generic be widely available?

First supplies are expected before the end of 2026, with broader availability in 2027, subject to country regulatory approvals and procurement.

Related coverage: Marathon Health data breach exposes 5.7 million people's medical and Social Security data and Federal hemp ban takes effect December 11, making most CBD and THC products illegal.